Khalid “Kal” Mentak, PhD Catalyst Technology Innovation Group Palo Alto, CA Empowering IP from Idea to Market The Glakolens Case

Historical Perspective Companies in the Biotech and Healthcare segment use Universities as fundamental research centers through sponsored research programs IP is assigned to sponsors through licensing agreements In most cases IP is not managed properly based on the lack of incentives for value creation

The landscape has changed Universities are taking a proactive approach to monetize IP independently of sponsors Incubators, accelerators, and investment centers are playing an increasing role in leveraging academic IP Better IP quality and management through outside due diligence and independent investors

The New Value Creation Model Bring investment, regulatory, and entrepreneurial expertise to universities Educate students and faculty members on how to integrate value creation into creating innovative IP Highlight the role of strong and well managed IP in improving lives and driving innovation

Bringing VCs, faculty members, and entrepreneurs together to drive healthcare innovation Educational curriculum with intensive interactions with the VC community in Silicon Valley A strong focus on creating and managing IP within the academic environment

Value-Driven IP creation Model Capital Clinical Need Project Generation IP Creation Strategy Management Business Advisory Group • Execution Plan • Milestones & Goals • First-in-Man Regulatory Advisory Group • Clinical Need Assessment • MKT Opportunity Assessment • Project Scope Analysis

The Glakolens Case Unmet Clinical Need Glaucoma is a chronic disease with no cure 70M people worldwide have glaucoma - €5B Market The 2nd leading cause of blindness globally It develops due to increased intraocular pressure (IOP) The ability to monitor IOP over an extended period of time is critical to delivering efficient therapy No viable product on the market

The Glakolens Case The Solution Development and market introduction of the first non- invasive wireless, contact lens- based IOP monitoring system capable of collecting data over prolonged periods of time

The Glakolens Case The Technology Based on a low cost and easy to manufacture passive biosensor. Accurately monitors fluctuations in IOP by measuring changes in the geometry of a sensor placed on the cornea. First non-invasive, wireless, and continuous IOP monitoring system

The Glakolens Case Investment-driven IP Assessment Value-driven evaluation Deep understanding of the glaucoma market KOL assessment Market acceptance Regulatory path Sales strategy Exit strategy

The Glakolens Case Conventional IP Assessment Patentability FTO Infringement Patent coverage based on business strategy

Leveraging IP to Get from Idea to Market Timeframe Milestone Year 1 Produce Prototype File for International Patent Year 2 Produce Functional Model Obtain Issued Patents Initiate Validation Year 3 Perform Full Validation Expand IP Strategic positioning for potential exit or licensing deal Pitch the product to various strategics in ophthalmology, optometry, and telemedicine Year 4 Obtain CE Mark Perform Clinical Validation Launch in Selected Markets